Clinical trials for Lung cancer
293 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Lung cancer
#NCT07222566
#2025-523461-17-01
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
BRAF
EGFR
MET
NTRK-1/2/3
RET
ROS-1
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Targeted therapy
3 recruiting sites
Pfizer
Phase 3
Lung cancer
#NCT06350097
#2023-509883-89-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
AstraZeneca
Phase 3
Lung cancer
#NCT07195695
#2025-521284-12-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Localized
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
EGFR
Excluded previous treatments at localized stage
Radiotherapy
7 recruiting sites
Boehringer Ingelheim
Phase 3
Lung cancer
#NCT05918302
#2022-502154-13-00
Required histologic types
Neuroendocrine tumor/carcinoma other than SCLC
Required histologic sub types
Neuroendocrine tumor/carcinoid
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
1
2
8 recruiting sites
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
Lung cancer
#NCT06801834
#2024-515884-69-00
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
12 recruiting sites
Gilead Sciences
Phase 3
Lung cancer
#NCT06422143
#2023-510128-66-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Immunotherapy
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Antibody Drug Conjugates (ADC)
5 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Lung cancer
#NCT07144280
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Pfizer
Phase 3
Lung cancer
#NCT07099898
#2025-521627-78
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
3 recruiting sites
GlaxoSmithKline
Phase 3
Lung cancer
#NCT06868277
#2024-517780-24-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
EGFR
ROS-1
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
11 recruiting sites
AstraZeneca
Phase 3
Lung cancer
#NCT06472245
#2023-509340-10-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded genetic anomalies
ALK
EGFR
ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
29 recruiting sites
OSE Immunotherapeutics